These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 22382618)

  • 61. Increased uptake of [¹²³I]meta-iodobenzylguanidine, [¹⁸F]fluorodopamine, and [³H]norepinephrine in mouse pheochromocytoma cells and tumors after treatment with the histone deacetylase inhibitors.
    Martiniova L; Perera SM; Brouwers FM; Alesci S; Abu-Asab M; Marvelle AF; Kiesewetter DO; Thomasson D; Morris JC; Kvetnansky R; Tischler AS; Reynolds JC; Fojo AT; Pacak K
    Endocr Relat Cancer; 2011 Feb; 18(1):143-57. PubMed ID: 21098082
    [TBL] [Abstract][Full Text] [Related]  

  • 62.
    Turnock S; Turton DR; Martins CD; Chesler L; Wilson TC; Gouverneur V; Smith G; Kramer-Marek G
    Sci Rep; 2020 Dec; 10(1):20918. PubMed ID: 33262374
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Preclinical Development of [211At]meta- astatobenzylguanidine ([211At]MABG) as an Alpha Particle Radiopharmaceutical Therapy for Neuroblastoma.
    Batra V; Samanta M; Makvandi M; Groff D; Martorano P; Elias J; Ranieri P; Tsang M; Hou C; Li Y; Pawel B; Martinez D; Vaidyanathan G; Carlin S; Pryma DA; Maris JM
    Clin Cancer Res; 2022 Sep; 28(18):4146-4157. PubMed ID: 35861867
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Improved outcome of
    Corroyer-Dulmont A; Falzone N; Kersemans V; Thompson J; Allen DP; Able S; Kartsonaki C; Malcolm J; Kinchesh P; Hill MA; Vojnovic B; Smart SC; Gaze MN; Vallis KA
    Radiother Oncol; 2017 Sep; 124(3):488-495. PubMed ID: 28595752
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Performing [
    Borgwardt L; Brok J; Andersen KF; Madsen J; Gillings N; Fosbøl MØ; Denholt CL; Petersen IN; Sørensen LS; Enevoldsen LH; Oturai PS; Johannesen HH; Højgaard L; Schulze C; Saxtoft E; Andersen F; Fischer BM
    J Nucl Med; 2024 Aug; 65(8):1286-1292. PubMed ID: 38960713
    [TBL] [Abstract][Full Text] [Related]  

  • 66. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
    Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
    J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Targeted radiotherapy of multicell neuroblastoma spheroids with high specific activity [125I]meta-iodobenzylguanidine.
    Roa WH; Miller GG; McEwan AJ; McQuarrie SA; Tse J; Wu J; Wiebe LI
    Int J Radiat Oncol Biol Phys; 1998 May; 41(2):425-32. PubMed ID: 9607361
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
    Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
    J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Diagnosis, Treatment Response, and Prognosis: The Role of
    Piccardo A; Morana G; Puntoni M; Campora S; Sorrentino S; Zucchetta P; Ugolini M; Conte M; Cistaro A; Ferrarazzo G; Pescetto M; Lattuada M; Bottoni G; Garaventa A; Giovanella L; Lopci E
    J Nucl Med; 2020 Mar; 61(3):367-374. PubMed ID: 31541036
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[(131)I]iodobenzylguanidine by neuroblastoma tumors.
    Carlin S; Mairs RJ; McCluskey AG; Tweddle DA; Sprigg A; Estlin C; Board J; George RE; Ellershaw C; Pearson AD; Lunec J; Montaldo PG; Ponzoni M; van Eck-Smit BL; Hoefnagel CA; van den Brug MD; Tytgat GA; Caron HN
    Clin Cancer Res; 2003 Aug; 9(9):3338-44. PubMed ID: 12960120
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Meta-iodobenzylguanidine in children.
    Gelfand MJ
    Semin Nucl Med; 1993 Jul; 23(3):231-42. PubMed ID: 8378796
    [TBL] [Abstract][Full Text] [Related]  

  • 72. 18F-FDG PET/CT and 123I-metaiodobenzylguanidine imaging in high-risk neuroblastoma: diagnostic comparison and survival analysis.
    Papathanasiou ND; Gaze MN; Sullivan K; Aldridge M; Waddington W; Almuhaideb A; Bomanji JB
    J Nucl Med; 2011 Apr; 52(4):519-25. PubMed ID: 21421719
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Therapeutic effect of m-[131I]- and m-[125I]iodobenzylguanidine on neuroblastoma multicellular tumor spheroids of different sizes.
    Weber W; Weber J; Senekowitsch-Schmidtke R
    Cancer Res; 1996 Dec; 56(23):5428-34. PubMed ID: 8968097
    [TBL] [Abstract][Full Text] [Related]  

  • 74. A phantom study: Should
    Beijst C; de Keizer B; Lam MGEH; Janssens GO; Tytgat GAM; de Jong HWAM
    Med Phys; 2017 May; 44(5):1624-1631. PubMed ID: 28273347
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Discrepant salivary gland response after radioiodine and MIBG therapies.
    Jentzen W; Richter M; Poeppel TD; Schmitz J; Brandau W; Bockisch A; Binse I
    Q J Nucl Med Mol Imaging; 2017 Sep; 61(3):331-339. PubMed ID: 25566809
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Dexmedetomidine does not interfere with meta-iodobenzylguanidine (MIBG) uptake at clinically relevant concentrations.
    Batra V; Makvandi M; Zuppa AF; Patel N; Elias J; Pryma DA; Maris JM
    Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27654664
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma.
    Taggart DR; Han MM; Quach A; Groshen S; Ye W; Villablanca JG; Jackson HA; Mari Aparici C; Carlson D; Maris J; Hawkins R; Matthay KK
    J Clin Oncol; 2009 Nov; 27(32):5343-9. PubMed ID: 19805691
    [TBL] [Abstract][Full Text] [Related]  

  • 78. [131I]metaiodobenzylguanidine in neuroblastoma patients at diagnosis.
    Mastrangelo R; Lasorella A; Troncone L; Rufini V; Iavarone A; Riccardi R
    J Nucl Biol Med (1991); 1991; 35(4):252-4. PubMed ID: 1823829
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Clinical performance and radiation dosimetry of no-carrier-added vs carrier-added 123I-metaiodobenzylguanidine (MIBG) for the assessment of cardiac sympathetic nerve activity.
    Verberne HJ; Sokole EB; van Moerkerken AF; Deeterink JH; Ensing G; Stabin MG; Somsen GA; van Eck-Smit BL
    Eur J Nucl Med Mol Imaging; 2008 Apr; 35(4):798-807. PubMed ID: 18183394
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study.
    Modak S; Zanzonico P; Carrasquillo JA; Kushner BH; Kramer K; Cheung NK; Larson SM; Pandit-Taskar N
    J Nucl Med; 2016 Feb; 57(2):231-7. PubMed ID: 26742708
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.